Recursion Pharmaceuticals (RXRX) Net Equity Issued and Repurchased (2020 - 2025)

Recursion Pharmaceuticals (RXRX) has 5 years of Net Equity Issued and Repurchased data on file, last reported at $133.4 million in Q4 2025.

• Quarterly Net Equity Issued and Repurchased rose 1109.25% year-over-year to $133.4 million in Q4 2025, while the trailing twelve-month figure through Mar 2026 was $487.8 million (up 47.58% YoY) and the FY2025 annual result came in at $528.9 million, up 76.04% from the prior year.
• Net Equity Issued and Repurchased fell to $133.4 million in Q4 2025, from $254.5 million in the prior quarter.
• In the past five years, Net Equity Issued and Repurchased ranged from a high of $462.9 million in Q4 2021 to a low of $10.9 million in Q1 2024.
• A 4-year average of $129.1 million and a median of $78.1 million in 2023 frame the typical range for Net Equity Issued and Repurchased.
• Annual changes were most pronounced in 2024 — Net Equity Issued and Repurchased plunged 85.88% — and 2025, when it soared 1399.65%.
• Tracing RXRX's Net Equity Issued and Repurchased over 4 years: stood at $462.9 million in 2021, then sank by 83.13% to $78.1 million in 2023, then sank by 85.88% to $11.0 million in 2024, then surged by 1109.25% to $133.4 million in 2025.
• The last three Net Equity Issued and Repurchased figures came in at $133.4 million (Q4 2025), $254.5 million (Q3 2025), and $100.0 million (Q2 2025), per Business Quant data.